Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets
Author(s): Kaila Nitin, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
Issue: May/Jun 2003 - Diabetes and Wound Care
View All Articles in Issue
Page(s): 233-239
Download in electronic PDF format for $75
Abstract: The qualification and quantification of dapsone in suspension were developed
and shown to be stability indicating by means of a reverse-phase high-performance
liquid chromatographic method. The real solubility of dapsone in water was
calculated to be 0.208 mg/mL at 25°C. The enthalpy of solution and the entropy
of solution were calculated to be -175.6 J/g and -43605.7 J/K/M, respectively. An
extemporaneous suspension was formulated from commercially available dapsone
tablets, and the chemical stability of dapsone in the suspension was determined
by means of accelerated stability testing. The 91-day analytical stability testing
study was conducted at 4, 30, 50, 60, and 70°C. The energy of activation for the
suspension was determined to be –23288.35 J/K/M. The zero-order rate of
degradation for dapsone (k0,25) in suspension at 25°C was found to be 0.040845
day-1. The first-order rate of degradation for dapsone in solution was found to be
0.196370 (mg/mL)(day-1). The shelf life for the suspension was calculated to be
31.67 days at 25°C and 230.76 days under refrigeration at 4°C.
Related Keywords:
Dapsone tablets, formulation development of extemporaneous suspension prepared from, Dapsone tablets, stability testing of extemporaneous suspension prepared from
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets
Kaila Nitin, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
|
May/Jun 2003
Pg. 233-239
|
Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Alexander Kenneth S, Thyangarajapuram N
|
Sep/Oct 2003
Pg. 389-393
|
A Pilot Stability Study of Dehydroepiandrosterone Rapid-dissolving Tablets Prepared by Extemporaneous Compounding
Rush Steven D, Vernak Charlene, Zhao Fang
|
Jan/Feb 2017
Pg. 83-87
|
Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets
Zaid Abdel Naser, Assali Mohyeddin, Qaddomi Aiman, Ghanem Mashhour, Zaaror Yara Abu
|
Mar/Apr 2014
Pg. 169-174
|
Extemporaneous Formulation and Stability Testing of Mexiletine HCl Solution
Alexander Kenneth S, Kaushik Sarita
|
Mar/Apr 2004
Pg. 147-152
|
Stability of Allopurinol Suspension Compounded from Tablets
Alexander Kenneth S, Davar Nipun, Parker Gordon A
|
Mar/Apr 1997
Pg. 128-131
|
Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets
Zaid Abdel Naser, Malkieh Numan, Kharoaf Maher, Ghoush Abeer Abu, Al-Ramahi Rowa'
|
Jul/Aug 2012
Pg. 342-346
|
Dapsone 2 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Nov/Dec 2017
Pg. 491
|
Dapsone 2-mg/mL in Oral Mix or Oral Mix SF Suspension
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 415
|
Physicochemical Stability of the Extemporaneous Ibuprofen Oral Suspension in "Wagner" Base
Spennacchio Antonio, Lopedota Angela, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio
|
Jan/Feb 2023
Pg. 72-77
|
Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients
de Lafuente Yanina, García Mónica Cristina, Jiminez-Kairuz Alvaro
|
Jul/Aug 2019
Pg. 324-331
|
Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
|
Jul/Aug 2020
Pg. 327-336
|
Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for Extemporaneous Compounding
Zhao Fang, Dave Vivek S, Mar Mazin Z, Perri Jonathan R
|
Sep/Oct 2018
Pg. 433-439
|
Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions
Kabiche Djamila, Balde Issa-Bella, Majoul Elyes, Kabiche Sofiane, Bourguignon Elodie, Fontan Jean-Eudes, Cisternino Salvatore, Schlatter Joel
|
Mar/Apr 2017
Pg. 160-163
|
The Formulation Development and Stability of Spironolactone Suspension
Alexander Kenneth S, Vangala Shyam Sundar KS, White Donald B, Dollimore David
|
May/Jun 1997
Pg. 195-199
|
The Formulation Development and Stability of Metronidazole Suspension
Alexander Kenneth S, Vangala Shyam Sundar KS, Dollimore David
|
May/Jun 1997
Pg. 200-205
|
Stability of an Oral Liquid Dosage Form of Glycopyrrolate Prepared from Tablets
Gupta Vishnu D
|
Nov/Dec 2001
Pg. 480-481
|
Stability of Sotalol Hydrochloride in Extemporaneously Prepared Oral Suspension Formulations
Sidhom Madiha B, Rivera Nadya, Almoazen Hassan, Taft David R, Kirschenbaum Harold L
|
Sep/Oct 2005
Pg. 402-406
|
Recent Formulation Advances and Preparation of Orally Disintegrating Tablets
Ejeta Fikadu
|
Sep/Oct 2022
Pg. 370-377
|
Dapsone 2 mg/mL in Ora-Sweet and Ora-Plus
Allen Loyd V Jr
|
Jan/Feb 2023
Pg. 52
|
Return to Top |